List view / Grid view
27 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the combination of Tafinlar and Mekinist for the treatment of adult patients with advanced melanoma...
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
16 July 2015 | By Victoria White
Coartem 80/480mg has received WHO prequalification, making it the first high strength ACT antimalarial treatment available for public sector procurement...
8 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Novartis' Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
29 June 2015 | By Victoria White
New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.
29 June 2015 | By Victoria White
Novartis has entered into an agreement to acquire Spinifex - a company focused on developing a peripheral approach to treat neuropathic pain...
26 June 2015 | By Victoria White
The CHMP of the EMA have adopted a positive opinion for panobinostat capsules for the treatment of patients with multiple myeloma...
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
10 June 2015 | By Victoria White
Novartis has announced new one-year study results from the MEASURE 2 pivotal Phase III study of secukinumab in ankylosing spondylitis (AS)...
22 May 2015 | By Victoria White
The Phase III study of everolimus in patients with advanced nonfunctional neuroendocrine tumours (NET) of GI or lung origin met its primary endpoint...
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
23 April 2015 | By Victoria White
The MHRA has granted a PIM designation for Novartis’ investigational medicine for patients with heart failure with reduced ejection fraction, LCZ696...
31 March 2015 | By Victoria White
Novartis has announced that the FDA has approved Jadenu tablets, a new oral formulation of Exjade® tablets, for the treatment of chronic iron overload...
